These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 ganglioside. Sinici I; Yonekawa S; Tkachyova I; Gray SJ; Samulski RJ; Wakarchuk W; Mark BL; Mahuran DJ PLoS One; 2013; 8(3):e57908. PubMed ID: 23483939 [TBL] [Abstract][Full Text] [Related]
4. The GM2 gangliosidoses databases: allelic variation at the HEXA, HEXB, and GM2A gene loci. Cordeiro P; Hechtman P; Kaplan F Genet Med; 2000; 2(6):319-27. PubMed ID: 11339652 [TBL] [Abstract][Full Text] [Related]
5. GM2 gangliosidosis AB variant: first case of late onset and review of the literature. Ganne B; Dauriat B; Richard L; Lamari F; Ghorab K; Magy L; Benkirane M; Perani A; Marquet V; Calvas P; Yardin C; Bourthoumieu S Neurol Sci; 2022 Nov; 43(11):6517-6527. PubMed ID: 35925454 [TBL] [Abstract][Full Text] [Related]
6. Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease. Karumuthil-Melethil S; Nagabhushan Kalburgi S; Thompson P; Tropak M; Kaytor MD; Keimel JG; Mark BL; Mahuran D; Walia JS; Gray SJ Hum Gene Ther; 2016 Jul; 27(7):509-21. PubMed ID: 27197548 [TBL] [Abstract][Full Text] [Related]
7. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis]. Tsuji D Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522 [TBL] [Abstract][Full Text] [Related]
15. Treatment of GM2 Gangliosidosis in Adult Sandhoff Mice Using an Intravenous Self-Complementary Hexosaminidase Vector. Osmon KJ; Thompson P; Woodley E; Karumuthil-Melethil S; Heindel C; Keimel JG; Kaemmerer WF; Gray SJ; Walia JS Curr Gene Ther; 2022; 22(3):262-276. PubMed ID: 34530708 [TBL] [Abstract][Full Text] [Related]
16. Systemic Gene Transfer of a Hexosaminidase Variant Using an scAAV9.47 Vector Corrects GM2 Gangliosidosis in Sandhoff Mice. Osmon KJ; Woodley E; Thompson P; Ong K; Karumuthil-Melethil S; Keimel JG; Mark BL; Mahuran D; Gray SJ; Walia JS Hum Gene Ther; 2016 Jul; 27(7):497-508. PubMed ID: 27199088 [TBL] [Abstract][Full Text] [Related]
17. Biochemical consequences of mutations causing the GM2 gangliosidoses. Mahuran DJ Biochim Biophys Acta; 1999 Oct; 1455(2-3):105-38. PubMed ID: 10571007 [TBL] [Abstract][Full Text] [Related]
18. Two patients from Turkey with a novel variant in the İnci A; Cengiz Ergin FB; Biberoğlu G; Okur İ; Ezgü FS; Tümer L J Pediatr Endocrinol Metab; 2021 Jun; 34(6):805-812. PubMed ID: 33819415 [TBL] [Abstract][Full Text] [Related]
19. GM2 gangliosidosis AB variant: novel mutation from India - a case report with a review. Sheth J; Datar C; Mistri M; Bhavsar R; Sheth F; Shah K BMC Pediatr; 2016 Jul; 16():88. PubMed ID: 27402091 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of a Bicistronic Vector for Correction of Sandhoff Disease in a Mouse Model. Woodley E; Osmon KJL; Thompson P; Richmond C; Chen Z; Gray SJ; Walia JS Mol Ther Methods Clin Dev; 2019 Mar; 12():47-57. PubMed ID: 30534578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]